There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:A61K47/68
Jump to navigation
Jump to search
Subcategories
This category has the following 27 subcategories, out of 27 total.
A
C
D
E
J
M
N
P
R
S
T
Y
Pages in category "A61K47/68"
The following 49 pages are in this category, out of 49 total.
1
- 18250727. SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18271206. MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS simplified abstract (The Regents of the University of California)
- 18277914. SINGLE DOMAIN ANTIBODY AGAINST CD47 AND USE THEREOF simplified abstract (SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION)
- 18277926. SINGLE DOMAIN ANTIBODY AGAINST PD-L1 AND USE THEREOF simplified abstract (SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION)
- 18302738. METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY simplified abstract (The Regents of the University of California)
- 18398557. METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION simplified abstract (NOVOCURE GMBH)
- 18411057. COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME simplified abstract (FUJIFILM Corporation)
- 18420955. METHODS OF MODELING LIQUID PROTEIN COMPOSITION STABILITY simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18480038. ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
- 18482223. HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
- 18546081. MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 simplified abstract (The Regents of the University of California)
- 18558013. Lipid Nanoparticle Therapeutics that Evade the Immune Response simplified abstract (The Trustees of the University of Pennsylvania)
- 18590455. PROGAMMABLE POLYMERIC DRUGS simplified abstract (SONY GROUP CORPORATION)
- 18602410. IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
- 18659241. COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR simplified abstract (GENENTECH, INC.)
- 18682046. FLOW THROUGH CATION EXCHANGE CHROMATOGRAPHY PURIFICATION PROCESSES FOR ANTIBODY DRUG CONJUGATES simplified abstract (GENENTECH, INC.)
- 18695618. PYRROLOBENZODIAZEPINE CONJUGATES FOR CANCER TREATMENT (Sony Group Corporation)
- 18695674. AUTOMATED SYNTHESIS OF POLYMERIC DUAL DRUGS (Sony Group Corporation)
- 18792232. CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18883719. COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS (The Johns Hopkins University)
- 18951146. BISPECIFIC HUMANIZED SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47, AND USE THEREOF (SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION)
B
- Biotechnology patent applications on 26th Jul 2024
- Biotechnology patent applications on 7th Mar 2025
- Biotechnology patent applications on January 2nd, 2025
- Biotechnology patent applications on July 25th, 2024
- Biotechnology patent applications on June 6th, 2024
- Biotechnology patent applications on March 6th, 2025
- Blockchain patent applications on February 22nd, 2024
- Blockchain patent applications on February 29th, 2024
- Blockchain patent applications on January 25th, 2024
D
- DNA Storage patent applications on 28th Feb 2025
- DNA Storage patent applications on February 27th, 2025
- DNA Storage patent applications on January 23rd, 2025
- DNA Storage patent applications on January 30th, 2025
- Dyne Therapeutics, Inc. (20250066495). MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MUSCULAR DYSTROPHY
- Dyne Therapeutics, Inc. (20250066496). MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
S
T
- TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, S.A. (20240245800). HIGHLY SPECIFIC RABBIT SINGLE -DOMAIN ANTIBODIES FOR DRUG DELIVERY IN IMMUNOTHERAPY APPLICATIONS simplified abstract
- The regents of the university of california (20240307550). MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS simplified abstract
- The regents of the university of california (20250066469). CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
- The Regents of the University of California patent applications on February 13th, 2025
- THE REGENTS OF THE UNIVERSITY OF CALIFORNIA patent applications on February 27th, 2025
- The Regents of the University of California patent applications on September 19th, 2024
